HighTower Advisors
NKTR icon

HighTower Advisors’s Nektar Therapeutics NKTR Stock Holding History

HighTower Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20
Closed -$1K – 2487
2019
Q3 		$1K Sell
20
-53
-73% -$19.4K ﹤0.01% 2395
2019
Q2 		$13K Sell
73
-247
-77% -$124K ﹤0.01% 2282
2019
Q1 		$2K Buy
320
+240
+300% +$142K ﹤0.01% 2255
2018
Q4 		$16K Hold
80
– – ﹤0.01% 2096
2018
Q3 		$16K Hold
80
– – ﹤0.01% 2176
2018
Q2 		$2K Buy
+80
New +$92.2K ﹤0.01% 2201
2018
Q1 		– Sell
-33
Closed -$4K – 2286
2017
Q4 		$4K Buy
+33
New +$19.5K ﹤0.01% 2216
2017
Q3 		– Sell
-107
Closed -$9K – 2321
2017
Q2 		$9K Buy
+107
New +$30.9K ﹤0.01% 2121

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

HighTower Advisors's NKTR Position: Q3 2024 in Review

HighTower Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2024, closing a stake of 1,241 shares — an estimated $22K sold.

HighTower Advisors first reported a position in NKTR in Q1 2016 and held it in 32 quarters. The position peaked at $1.96M in Q1 2018. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2024.

  • HighTower Advisors reported no remaining Nektar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HighTower Advisors sold 1,241 Nektar Therapeutics shares in Q3 2024, an estimated $22K.
  • HighTower Advisors first reported a position in Nektar Therapeutics in Q1 2016 and held it in 32 quarters.
  • HighTower Advisors's Nektar Therapeutics position peaked at $1.96M in Q1 2018.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2024.

Based on HighTower Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.